The stock exhibits a strong recovery trend over the past year, with a 1-year price change of +48.2%, significantly outperforming the S&P 500's +20.6%. Currently trading at $19.83, it sits at 69% of its 52-week range ($11.63–$25.12), indicating it has reclaimed a substantial portion of its highs but remains below the peak. This positioning suggests bullish momentum is intact but not overextended, leaving room for further upside if catalysts materialize. Short-term momentum shows a divergence: the 1-month change is -3.6% while the 3-month change is -3.3%, contrasting with the strong 1-year trend. This recent pullback from the June highs (near $24) could signal a temporary consolidation or profit-taking after a sharp rally, rather than a trend reversal, especially given the stock's beta of 1.05, which aligns closely with the market. The 52-week low of $11.63 provides a solid support level, while the 52-week high of $25.12 acts as key resistance. A breakout above $25.12 would signal a resumption of the uptrend, while a breakdown below $11.63 would negate the recovery. With a beta near 1.0, the stock's volatility is in line with the broader market, reducing the need for outsized risk adjustments.

Revenue growth is robust and accelerating: Q4 2025 revenue of $1.013 billion grew 44.4% year-over-year, up from $701 million in Q4 2024. The trailing twelve-month revenue reached approximately $3.95 billion, driven by strong premium and capitation revenue segments ($425.8M and $33.2M, respectively). This growth trajectory underscores the company's success in expanding its Medicare Advantage membership base. Profitability remains mixed but improving. The company reported a net loss of $11.0 million in Q4 2025, narrowing from a $31.1 million loss in Q4 2024, with gross margin improving to 10.5% from 12.3% a year ago. However, Q2 and Q3 2025 showed net profits of $15.7M and $3.7M, respectively, indicating a seasonal pattern. The operating margin turned positive at 0.4% for the trailing twelve months, a significant improvement from negative margins in prior periods. The balance sheet is moderately leveraged with a debt-to-equity ratio of 1.89 and a current ratio of 1.74, indicating adequate liquidity. Free cash flow turned positive on a trailing twelve-month basis at $123.7 million, a sharp reversal from negative FCF in prior years, suggesting the company is now generating cash to fund operations internally. ROE remains slightly negative at -0.4%, but the trend is improving as profitability increases.